Weekly Movers: PTC Therapeutics, Celator Pharmaceuticals, Chiasma, Sarepta and more…
April 25, 2016Research and Development, Sales and Marketing
With the earnings season in full swing this week investors focussed on the impact on stock moves as companies declared …
Pfizer, GSK’s anti-smoking drugs not linked to increase in serious neuropsychiatric adverse events – Study
April 25, 2016Research and Development, Sales and Marketing
Pharma giant Pfizer’s (NYSE: PFE) smoking cessation drug Chantix (varenicline) did not show an increase in serious neuropsychiatric adverse events …
Valeant receives further default notices due to its delayed 10-K filing
April 25, 2016Medical Communications, Sales and Marketing Valeant, default, risk, trouble, worry
Valeant Pharmaceuticals has issued a statement detailing that they have received additional notices of default under indentures due to its …
Merck’s colorectal cancer drug meets primary endpoint in Phase III study
April 25, 2016Research and Development, Sales and Marketing Erbitux, Merck, Serono, cancer drugs, colorectal cancer, increased survival, oncology, phase 3, phase III
Merck (FWB: MRK) has announced that its Phase III clinical trial of Erbitux, in combination with Folfox, met its primary …
AstraZeneca to sequence genomes to develop new drugs
April 22, 2016Medical Communications, Sales and Marketing AstraZeneca, Finland, Wellcome Trust, collaboration, genome, genomics, human longevity, institute for molecular medicine, sanger institute
AstraZeneca (LSE: AZN) has announced an integrated genomics initiative that aims to transform the drug discovery and development across is …
AbbVie announces further industry and academic collaborations
April 22, 2016Medical Communications, Research and Development AbbVie, collaboration, commercialisation, cytomx, partnership, research, university of chicago
AbbVie (NYSE: ABBV) has announced further collaborations that will see it partner with industry and academia to develop oncology candidates …
Biogen Q1 profits rise boosted by Tecfidera sales
April 22, 2016Medical Communications, Sales and Marketing Biogen, Q1, biotech, earnings, results, tecfidera
Shares in Biogen (Nasdaq: BIIB) climbed to close up over 5% Thursday after the company reported 18% rise in first-quarter …
Novartis muscular drug fails in Phase III trials
April 22, 2016Medical Communications, Research and Development FDA, Novartis, bimagrumab, breakthrough, morphosys, muscular, phase III
A muscular drug developed by Novartis (NYSE: NVS), in partnership with MorphoSys (ETR: MOR), failed to meet its primary endpoint …
Actelion ups outlook for 2016, reports Q1 net income up 12%
April 22, 2016Medical Communications, Sales and Marketing Actelion, Biotechnology, Q1 results, earnings, outlook
Swiss biotech company Actelion (VTX: ATLN) raised its outlook for 2016 and reported a 12% rise in first quarter net …
A win for Sanofi on Jevtana after NICE reverses guidance
April 22, 2016Medical Communications, Sales and Marketing Cancer Drugs Fund, Jevtana, NICE, Sanofi, recommendation, reversal
Prostate cancer treatment Jevtana (cabazitaxel), marketed by Sanofi (NYSE: SNY) has been recommended by NICE in its final guidance. The …
Bluebird Bio gene therapy posts encouraging results in treatment of rare brain disease
April 21, 2016Medical Communications, Research and Development Bluebird Bio, Phase II, gene therapy, lenti-d, paediatric, phase 2, phase 3, phase III, rare brain disease
Bluebird bio (NASDAQ: BLUE) has announced positive interim data from a Phase II/III trial evaluating their Lenti-D gene therapy in …
PCI Pharma Services’ Ian Parsonage to Share Serialization Expertise at Global Track & Trace Conference
April 21, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ian parsonage, pci pharma, serialisation
Ian Parsonage, Senior Director of Global Serialization for leading pharmaceutical services provider PCI Pharma Services, will present at the Global …
Shares plunge at Sarepta after negative FDA review on muscle disorder drug
April 21, 2016Research and Development, Sales and Marketing FDA, Sarepta Therapeutics, Shares, dive, fall, negative, plunge, sarepta
Sarepta Therapeutics (NASDAQ: SPRT) is counting the cost as shares plunge following a negative review given by staff at the …
GW Pharma’s cannabis-based epilepsy drug granted orphan designation by FDA
April 21, 2016Research and Development, Sales and Marketing GW Pharma, cannabis, cannabis-based, epilepsy
GW Pharmaceuticals (NASDAQ: GWPH) has announced that the US Food and Drug Administration has granted its cannabis-based epilepsy drug, Epidiolex …
Novartis drug Afinitor significantly reduces seizures in TSC patients
April 21, 2016Research and Development Afinitor, Novartis, Tuberous Sclerosis Complex, drug, seizure, seizures, tsc
Novartis (SIX: NOVN) has announced the results from a Phase III clinical trial which shows that Afinitor (everolimus) significantly reduced …
BioMarin announces positive data from early stage trials of haemophilia A gene therapy
April 21, 2016Research and Development BioMarin Pharmaceutical, Phase II, drug trial, haemophilia A gene therapy
BioMarin Pharmaceutical (Nasdaq: BMRN) said early-stage trials for its haemophilia A gene therapy showed encouraging data. Chief Medical Officer, Hank …
Amgen’s drug reduces rates of bleeding in rare childhood disorder
April 21, 2016Research and Development, Sales and Marketing Amgen, blood disorder, children, nplate, paediatric, platelet, rare, romisplostim
Amgen (NASDAQ: AMGN) has announced the results of a Phase III trial, published in The Lancet, which shows that Nplate …
Novartis Q1 earnings drop as cancer drug sales falter
April 21, 2016Business Services, Sales and Marketing Financial, Novartis, earnings, first quarter, results
Swiss drugmaker Novartis (SIX: NOVN) on Thursday reported a 13% drop in net income for the first quarter on the …
Abbvie acquires immune-oncology target from argenx
April 21, 2016Research and Development, Sales and Marketing AbbVie, Protein, argenx, garp, immuno-oncology, immunosuppresive
AbbVie (NYSE:ABBV) has announced the acquisition of a new preclinical-stage human antibody program evaluating the novel immune-oncology target GARP, a …
Illumina shares plunge as it cuts Q1 outlook
April 20, 2016Research and Development, Sales and Marketing Financial, Illumina, Share price, Shares, outlook, revenue, stock market
Shares in Illumina (Nasdaq: ILMN) plunged after the company cut its revenue estimates for the first quarter based on low …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
